Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win [Yahoo! Finance]
Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound [Yahoo! Finance]
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer [Yahoo! Finance]
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Novo Nordisk Stumbles as Obesity Drug Race Heats Up [Yahoo! Finance]